Recruitment of immune cells to tumor cells targeted by a therapeutic antibody can heighten the antitumor efficacy of the antibody. For example, p185
Introduction
Antibody-based cancer therapies, which in general target cell surface tumor antigens with recombinantly engineered monoclonal antibodies, have changed the paradigm of treatments for many types of tumors (1) . These monoclonal antibodies (mAb), either as humanized antibodies or chimeric molecules, contain the Fc region of human IgG molecules that is required to induce cytotoxic mechanisms, such as ADCC and CDC.
Recombinant antibodies have to be expressed in mammalian cells to obtain proper glycosylation, which is required to keep the Fc region of the IgG molecule in an "open" conformation to interact with Fc receptors (2) . However, glycosylation increases the complexity of mAb production for therapeutic use. Depending on cell culture conditions, the produced monoclonal antibodies can have varied glycosylation (3) , which can either extend or shorten the serum half-life of the antibodies (4) (5) (6) , and cause side effects in some antibody -based treatments (7) . her2/neu belongs to the ErbB family of receptor tyrosine kinases (RTK), which includes four members: ErbB1/EGFR (epidermal growth factor receptor), ErbB2/ p185 her2/neu (also known as Neu, HER2/neu), ErbB3/HER3, and ErbB4/HER4 receptors. When activated by extracellular ligands, ErbB receptors will form catalytically active homodimeric, heterodimeric or oligomeric complexes. These complexes can lead to alterations of cellular growth and differentiation status. ErbB ligands and subsequent receptormediated signalings have been implicated in survival, proliferation and differentiation in a variety of cell types (reviewed in (8) (9) (10) ). After p185 her2/neu was identified as the oncoprotein in the neu oncogene transformed cells (11) , monoclonal antibodies to this oncoprotein and subsequently to the human homologues have been developed to reverse the transformed phenotype of cancer cells (12) (13) (14) (15) .
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Author Manuscript Published OnlineFirst on February 8, 2013 ; DOI: 10.1158/0008-5472. The humanized anti-p185 her2/neu antibody, h4D5 (trastuzumab, Herceptin), is approved to treat breast and stomach cancers. We have defined a constrained peptide, AHNP, based on the CDR3.H loop from h4D5 (16) . Binding of AHNP to p185 her2/neu suppresses the proliferation of p185 her2/neu transformed cells in vitro and in vivo. We have also grafted AHNP to the tetrameric scaffold of streptavidin and established a recombinant protein, ASA (17) , which possesses significantly improved biological activity. ASA demonstrates higher association rate binding to p185 her2/neu (K on ), a feature explained by the avidity contributed by the tetrameric structure. However, both the AHNP peptide and the ASA protein lack the capability to trigger Fc dependent effector functions.
Here we report an approach to enlist CDC/ADCC functions to these small recombinant proteins by incorporating the Z domain derived from Protein A. This class of novel proteins are termed "Grababody", as they are able to capture circulating IgGs while binding to target antigens. The captured IgG can further direct complement complexes and immune effector cells carrying Fc receptors to tumor cells expressing targeted receptors. This approach bypasses the need for Fc region and thus avoid glycosylation issues, allowing the facile production of the protein in bacteria. supplemented with 10% heat inactivated fetal calf serum, L-glutamine (2mM), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37°C in a humidified 5% CO2 atmosphere.
Materials and Methods

Cell lines and reagents
All cell lines were routinely checked for mycoplasma.
The pIG6-4D5noSS plasmid, which contains the scFv cDNA of h4D5, was obtained from Prof. A. Plückthun, University of Zürich, Zürich, Switzerland (19) . The plasmid pEZZ18 that contains the protein A cDNA sequence was purchased from GE Healthcare Life Sciences.
Construction of plasmids
The following primers were used to amplify the cDNAs for 4D5scFV and the ZZ domain: for 4D5scFv, primer4D5s (5'-GGGACCATGGCTGATATCCAGATGACC CAGTCTCCGAGC-3') and 4D5salI (5'-GGGAGTCGACAGAGCCACCACCGCC AGAAGAAACGGTAACGGT-3'); for ZZ: ZZsal74 (5'-GGGAGTCGACGTAGACAA CAAATTCAAC-3') and ZZrxho (5'-GGGACTCGAGTTTCGGCGCCTGAGC-3'). The amplified cDNAs were digested with restriction enzymes NcoI/SalI (for 4D5scFv) and SalI/XhoI (for ZZ) and ligated together into the bacterial expression vector pET21d to express 4D5scFvZZ. The cDNA for 4D5scFv was also cloned into pET21d to express the scFv as the control.
OD at 600nm reached 1.0, recombinant proteins were induced to express with 0. was regenerated after each cycle using 10 mM NaOH and 0.1% SDS (w/v). The K on value was determined from a plot of (ln(dR/dt))/t vs Ab concentration. The K off was determined from the dissociation part of the sensorgram at the highest concentration of Ab used, with a flow rate of 15 ml/minute to prevent rebinding. The equilibrium dissociation constant (K D ) was calculated as the k off /k on ratio.
CDC measured by MTT assay
The CDC activity was measured using mouse serum as the resource for complements as we have reported previously (20) . Briefly, T6-17 cells were divided into aliquots (4,000 -5,000 cells/well) into 96-well flat-bottom plates and treated with 4D5scFv, 4D5scFvZZ or humanized h4D5 mAb (positive control) in the presence of 5% FBS (control) or mouse serum. Cells were incubated for 3 days at 37°C in a humidified atmosphere with 5% CO 2 .
Research. Old medium was carefully removed and replaced with 100 μl fresh medium, in which cells were incubated for another 4 hours. A total of 25 μl of MTT solution (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, 5 mg/ml in PBS) was added to each well, and after 2 h of incubation at 37°C, 100 μl of the extraction buffer (20% w/v SDS, 50% N,N-dimethyl formamide, pH 4.7) was added. After an overnight incubation at 37°C, the absorbance at 570nm was measured using an ELISA reader. 
Xenograft studies
Research. and CH2 domain Fc, Protein A interacts with the elbow region connecting CH2 and CH3
( Figure S1 ). Based on these structural studies, we determine that Fc can interact with both Fc receptor and the Z domain simultaneously without steric hindrance.
Research. 
The Z domain is thus grafted into several tumor antigen-binding proteins to obtain a class of recombinant proteins termed "Grababody". In this report, we fused the Z domain to the c-terminus of 4D5scFV to obtain the Grababody 4D5scFVZZ, anticipating that the IgG molecule recruited by 4D5scFvZZ would be able to interact with Fc receptors on immune effector cells.
Binding of the Grababody 4D5scFvZZ to p185
her2/neu receptor on the cell surface
We first tested the ability of 4D5scFvZZ to bind to p185 her2/neu on the surface of several cell lines, including the transformed T6-17 cells (NIH3T3 overexpressing human p185 her2/neu ) and two human breast cancer cell lines, SKBR3 and BT474. As shown in Table 1) . On the control cell lines NIH3T3 and Jurkat, neither 4D5scFv nor 4D5scFvZZ displayed any significant bindings ( Fig.1 G-J) .
Determination of the intrinsic affinity of 4D5scFvZZ to the antigen and IgG
To determine if the incorporation of the Z domain affects intrinsic binding kinetics, we compared 4D5scFv and 4D5scFvZZ for binding to p185 her2/neu in surface plasmon resonance (SPR) studies. Previously, we had established an Fc fusion construct containing the p185 her2/neu ectodomain (ECD) for SPR studies (17), but it was not ideal for this study since the Fc region by itself could interact with the Z domain. The p185
her2/neu fragment had to be expressed without the Fc tag.
The co-crystal structure of h4D5 and p185 her2/neu ectodomain (26) reveals that the h4D5 epitope is contained in the domain IV region of p185 her2/neu . However, a very short flexible region in the domain IV prevents the expression of the complete domain in bacteria. We expressed a slightly shortened version of domain IV containing a.a. residues 508-577 (Fig. S2 ). This fragment binds to mAb h4D5 in immunoprecipitation and in SPR assay as well ( Fig. S2 and Fig. S3 ). D4(508-577) also binds to the original mAb 7.16.4 that shares the epitope with h4D5 (15) (Fig. S3 ).
Using chip-immobilized p185 her2/neu domain IV, D4(508-577), the SPR experiment confirmed that the addition of the Fc-binding domain to scFv did not significantly change the intrinsic affinity to p185 her2/neu D4(508-577) (K D : 4D5scFv, 145nM; 4D5scFvZZ: 112 nM) (Fig. 2 A&B) . The humanized mAb h4D5, which contains human IgG1 Fc region, was also immobilized to chip. Only 4D5scFvZZ showed a very high affinity to this IgG (K D : 1.3 nM). The Z domain may also lead to intermolecular association as a modest affinity was detected between 4D5scFvZZ molecules (Kd = 946 nM).
Simultaneous binding of 4D5scFvZZ to p185 her2/neu and human IgG
Research. To demonstrate that the Z domain in the Grababody is available to bind IgG after it forms a complex with the receptor, we performed a sequential binding experiment by SPR. The immobilized D4(508-577) was first contacted with 4D5scFvZZ and binding was detected.
After the dissociation phase of the first binding, we flowed over the D4(508-577)-4D5scFvZZ complexes with antibodies containing human Fc: mAb C225 (2 mg/ml, Fig   2C) or 2C4 (0.5 mg/ml, Fig 2D) . C225 is specific to human EGFR. Although 2C4 binds to p185 her2/neu , it binds to an epitope in Domain II. None of these two antibodies binds to the D4(508-577) fragment (Fig. S3 ) but would be able to interact with the Z domain. As expected, binding was observed for the D4(508-577)-4D5scFvZZ complexes (Fig. 2 C&D).
Induction of immune effector cell function by 4D5scFvZZ
To investigate if the Grababody can lead to antibody mediated effector functions, we performed in vitro experiments to test both CDC and ADCC activities. 4D5scFvZZ-induced CDC was evaluated by MTT assay in the presence of mouse serum, which can be a good source of complements and has been shown to provide higher inhibition activity in this type of assay when compared with human serum (20) . As shown in Figure   3 , a significant inhibition of T6-17 proliferation was observed with 4D5scFvZZ in a dosedependent manner in 5% mouse serum, but not in 5% FBS. 4D5scFv also showed some proliferation inhibition activity in mouse serum, but the activity was weak. As the positive control, the humanized antibody h4D5 showed the very strong inhibition (~ 55%) in the presence of mouse serum.
ADCC of 4D5scFvZZ against BT474 breast cancer cells was measured in vitro by the calcein release assay, a non-radioactive alternative to the traditional Cr 51 assay (27) .
Human PBMC were used as effector cells. ADCC activity (~65%) can be observed with 10 ȝg/mL of 4D5scFvZZ, at an effector-to-target cell ratio of 25:1 and in the presence of 100 ȝg/mL human IgG (Fig 4) . Compared with human IgG only, no significant ADCC activity was observed with 4D5scFv. We could not detect any significant ADCC activity for 4D5scFvZZ towards control cell lines A431 and NIH3T3, or towards BT474 when human IgG antibodies were not supplemented. These studies confirmed that 4D5scFvZZ induced ADCC towards p185
her2/neu -expressing tumor cells in an IgG-dependent manner.
In vivo activity of 4D5scFv vs. 4D5scFvZZ
To examine if the Z domain in the Grababody actually improves anti-tumor activity, we studied in vivo tumor growth using the transformed cell line T6-17 that expresses human CAN-12-3920 non-human sequence in reagents developed for human use. It should be pointed out that Staphylococcus aureus is a very common pathogen and to which most people have been exposed. It is estimated that about 80% of individuals have nasal carriage of Staphylococcus aureus and 20-30% of the human population have persistent S. aureus colonized in the anterior nares (32, 33) .
One immunological concern of SpA relates to its binding to Fab region of human immunoglobulins, primarily those of VH3 origin (34) . Because of this binding capability, SpA is also expected to bind VH3-encoded B-cell antigen receptors, leading to the selection of these B cells and production of antibodies accordingly (35, 36) domain, to induce sTNFR1 is minimal (39), we do not expect our Grababody to have any significant effect on TNFR1.
Although we only showed a p185 her2/neu Grababody constructed from the scFv of h4D5, similar proteins can be generated using smaller antibody derived fragments, e.g. the constrained CDR3 from the heavy chain (data not shown). These shorter antibody fragments in general have a weaker affinity than the whole antibody molecule, but the affinity can be optimized through a variety of techniques. In addition, the half-life of the Grababody may not yet be ideal. In a very recent study, the IgG binding B domain was
proposed as a way to extend the plasma half-life of scFv approximately 6 times (42). We expect the p185 her2/neu Grababody to have a similar serum half-life of ~12 hours, but that will still be shorter than the half-life of 7-10 days for IgG. The less than ideal affinity as well as half-life suggest that we need to use a higher dosage of Grababody than the antibody to obtain similar levels of in vivo activity (Figs 5 and S4 ).
In addition to the future optimization of the affinity and half-life, we recognize that there is still room for improvement for the Z domain in the Grababody. The Z domain could be deimmunized and humanized for future use in human (43) . Furthermore, it appears that the IgG binding domain can be shortened. Braisted and colleagues reported a shorter version of the Z domain with slightly reduced affinity to Fc (Kd = 43 nM, vs 10 nM of the Z domain) (22) . ҏ In a followup study, a disulfide bond was used to constrain the conformation of the mini-Z domain to improve binding to Fc (44) .
In summary, we have developed a "proof of concept" class of novel recombinant proteins to direct endogenous antibody to tumor cells. μg/ml) and human IgG (100 μg/ml) (A). A significant increase of ADCC activity was observed when 10 μg/ml of 4D5scFvZZ was used (t test, p< 0.05) as compared with human IgG alone. In contrast, no activity was detected when 4D5scFv was used under similar conditions. ADCC activity of 4D5scFvZZ was dependent on the supplemented human IgG (B). In the absence of human IgG, only the h4D5 antibody showed very significant ADCC activity (p < 0.01). No significant ADCC activity was detected for 4D5scFvZZ on control cell lines A431 (C) and NIH3T3 (D). The size of tumors was very significantly different from the controls (t test, p < 0.01). No statistical difference was observed for 4D5scFv treatment although more mice were used.
Control: n= 9; 4D5scFv: n=11; 4D5scFvZZ: n=4.
